Litcius/Paper detail

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

Bruno Paiva, María‐Belén Vídriales, Amparo Sempere, Fabián Tarín, Enrique Colado, Celina Benavente, María‐Teresa Cedena, Joaquín Sánchez, Teresa Caballero‐Velázquez, Lourdes Cordón, Juan‐José Garcés, Catia Simoes, David Martínez‐Cuadrón, Teresa Bernal, Carmen Botella, Sofía Grille, Josefina Serrano, Carlos Rodríguez‐Medina, Lorenzo Algarra, Juan Manuel Alonso‐Domínguez, María‐Luz Amigo, Manuel Barrios, Raimundo García‐Boyero, Mercedes Colorado, Jaime Pérez-Oteyza, Manuel Pérez‐Encinas, Lisette Costilla-Barriga, María-José Sayas, Olga Pérez, Marcos González, José Antonio Pérez‐Simón, Joaquín Martínez‐López, Claudia Sossa, Alberto Órfão, Jesús F. San Miguel, Miguel Á. Sanz, Pau Montesinos, PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group

2021Leukemia43 citationsDOI

Topics & Concepts

MedicineOncologyMyeloid leukemiaMinimal residual diseaseInternal medicineCumulative incidenceMultivariate analysisDiseaseRisk stratificationLeukemiaImmunologyTransplantationAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchHematopoietic Stem Cell Transplantation
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia | Litcius